\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationOnline
ProgrammesDuring this infoday, the next funding opportunities for Sustainable and Smart Cities and Communities will be presented. The focus will be on areas such as Data Spaces for Smart Communities, Digital Solutions for the New European Bauhaus, and Living-in.eu governance.
9:30 - Introduction (purpose, topics, deadlines, where to find the info, and agenda for the day)
9:45 - CSA1 Presentation - Preparatory actions for Data Space for Smart Communities
10:00 - CSA2 Presentation - Governance of Living-in.eu community
10:15 - CSA3 Presentation - Digital Solutions in support of the New European Bauhaus
10:30 - Questions from the audience and answers
11:00 - Online networking for CSA1
11:30 - Online networking for CSA2
12:00 - Online networking for CSA3
12:30 - Final messages
Please register via the event website if you want to attend this event.
In the process of registration you will be asked if you would like to present your idea for one (or more) of the three CSAs in each of the networking sessions. In case you do, please prepare one slide with the CSA you are proposing, title of your proposal and main objectives, partners and which expertise and needs you have. The Commission will try to accommodate everyone of you and still give you time for networking.
The Commission may select speakers according to the timing available.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
